UBRELVY™ is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks. The therapy is taken by the user once a migraine starts — UBRELVY then provides relief for up to 24 hours. Yourway supports a patient-centric supply chain so that drugs in clinical trials can reach patients faster, regardless of where they are located.